Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
